Infliximab (Remicade) Lyophilized Powder from Japan
Infliximab is a chimeric monoclonal antibody against TNF-alpha for psoriasis and ulcerative colitis. HTS 3002.15.00.11 applies to this biotech-derived immunological product in measured retail doses for reconstitution.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Document lyophilization process and monoclonal origin; FDA requires stability post-reconstitution
• Declare as 'immunological product containing monoclonal antibodies' explicitly
• Avoid classifying with general cytokines; specify antibody fraction